Objective: Angiographic embolization is an established method of treating intractable cases of posterior epistaxis. This study aimed to test the effectiveness and safety of this method in treating cases refractory to conservative methods.
Methods: A descriptive retrospective analysis of consecutive cases referred to the department of interventional radiology with refractory epistaxis from January 2001 to December 2018 and received a selective angiographic embolization of the sphenopalatine artery was done. Only epistaxis of idiopathic origin was included in the study.
Results: During this period, 98 embolizations were performed. The success rate reached 81.6%. Minor complications were registered in 5%, with no single major complication. The length of stay was 10.5 ± 5.6.
Conclusion: Selective angiographic embolization is an effective, safe, and minimally invasive method in treating refractory epistaxis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161303 | PMC |
| http://dx.doi.org/10.1177/20503121231170478 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endovascular arterial embolization versus conservative management with nasal packing alone for severe epistaxis: a nationwide cohort study.
J Neurointerv Surg
December 2024
Interventional Neuroradiology, University of Maryland, College Park, Maryland, USA
Background: Endovascular arterial embolization (EAE) is an effective treatment for severe epistaxis refractory to conservative management with nasal packing. However, contemporary real-world data are lacking, as are data on head-to-head comparisons of EAE versus nasal packing alone.
Methods: This was a retrospective cohort study of the Nationwide Readmissions Database (NRD) from 2016 to 2021 in the United States.
COVID-19-Associated Immune Thrombocytopenic Purpura in a Hemodialysis Patient.
J Blood Med
November 2024
Kidney Institute of PLA, Department of Nephrology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, People's Republic of China.
Background: Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection has been a global threat since the end of 2019. Although the main clinical manifestation of coronavirus disease 2019 (COVID-19) is respiratory, its range of clinical manifestation is extensive and may include various systems, including hematological disorders, such as lymphopenia, thrombotic events, thrombocytopenia and immune thrombocytopenic purpura (ITP). The present case was the first one that aimed to raise awareness of ITP induced by COVID-19 in patients undergoing maintenance hemodialysis.
View Article and Find Full Text PDFPazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding.
J Thromb Haemost
October 2024
Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, USA.
Background: Hereditary hemorrhagic telangiectasia (HHT) is a bleeding disorder characterized by arteriovenous malformations, commonly presenting with epistaxis and gastrointestinal (GI) bleeding. Bleeding symptoms may be difficult to manage and may become life-threatening, with many patients developing dependence on parenteral iron and/or blood transfusion. There is a growing body of evidence that antiangiogenic therapies may be effective in management of bleeding symptoms, presumably targeting pathogenic HHT pathways such as vascular endothelial growth factor receptor.
View Article and Find Full Text PDFSevere Immune Thrombocytopenic Purpura in a Pediatric Patient With Fanconi Anemia: A Case Report.
Cureus
September 2024
General Practice, King Khalid University, Abha, SAU.
Article Synopsis
- Fanconi anemia (FA) is a rare genetic disorder causing bone marrow failure and a higher cancer risk, where autoimmune issues like immune thrombocytopenic purpura (ITP) are quite uncommon.
- A case report details a six-year-old boy with FA who developed severe ITP, presenting challenges in management due to extremely low platelet counts and spontaneous bruising.
- Treatment included intravenous immunoglobulin and corticosteroids, which initially helped, but he ultimately responded well to rituximab, leading to improved platelet counts and a stable condition at follow-up.
Outpatient management of pediatric epistaxis: A cost analysis and clinical model.
Laryngoscope Investig Otolaryngol
October 2024
Objectives: Pediatric epistaxis is a common, often non-operative condition encountered by Otolaryngologists. The present study seeks to (1) describe our outcomes of epistaxis management, (2) estimate the associated healthcare burden, and (3) propose a clinical model to optimize care coordination with primary care and advanced practice providers.
Methods: Retrospective case series of pediatric patients treated outpatient for epistaxis by a single otolaryngologist from 2021 to 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!